polycystic kidney diseases |
Disease ID | 1121 |
---|---|
Disease | polycystic kidney diseases |
Manually Symptom | (Waiting for update.) |
Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:19) C0020538 | hypertension | 11 C0022658 | renal disease | 10 C0009450 | infection | 10 C0022661 | end-stage renal disease | 8 C0035078 | renal failure | 8 C0340643 | aortic dissection | 4 C0030193 | pain | 4 C0007134 | renal cell carcinoma | 3 C0019080 | hemorrhage | 2 C0007766 | intracranial aneurysms | 2 C0022661 | chronic renal failure | 2 C0086445 | idiopathic membranous nephropathy | 2 C0041948 | uremia | 1 C0267834 | liver cyst | 1 C0917996 | cerebral aneurysm | 1 C0403383 | renal cyst infection | 1 C0033687 | proteinuria | 1 C0009714 | congenital hepatic fibrosis | 1 C0241961 | renal angiomyolipoma | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
---|
(Waiting for update.) |
All Snps(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Annotation(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Snp Trait(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
Mapped by lexical matching(Total Items:0) |
---|
(Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
---|
(Waiting for update.) |
Chemical(Total Drugs:2) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
C0022680 | rosiglitazone | C089730 | - | polycystic kidney diseases | MESH:D007690 | therapeutic | 20507283 | ||
C0022680 | sirolimus | D020123 | 53123-88-9 | polycystic kidney diseases | MESH:D007690 | therapeutic | 19321761 |
FDA approved drug and dosage information(Total Drugs:2) | ||||||||
---|---|---|---|---|---|---|---|---|
DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
MESH:D007690 | rapamune | sirolimus | 1MG/ML | SOLUTION;ORAL | Prescription | None | Yes | Yes |
MESH:D007690 | rapamune | sirolimus | 1MG | TABLET;ORAL | Prescription | AB | Yes | No |
FDA labeling changes(Total Drugs:2) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
MESH:D007690 | 11/3/2005 | rapamune | sirolimus | Prophylaxis of organ rejection in patients undergoing renal transplants | Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric ( | Labeling | B | - | - | - | Wyeth | 11/17/2004 | FALSE' |
MESH:D007690 | 11/3/2005 | rapamune | sirolimus | Prophylaxis of organ rejection in patients undergoing renal transplants | Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric ( | Labeling | B | - | - | - | Wyeth | 11/17/2004 | FALSE' |